Myeloproliferative Neoplasms

Comparison of Systemic Therapies for MPN Subtypes in the Real-World Setting

By

Susan Moench, PhD, PA-C

Publish Date December 23, 2020

In this prospective study, the efficacy and safety of conventional therapy, pegylated interferon alpha-2a, and ruxolitinib in the treatment of MPNs were compared.

Mortality Rates, Diverse Causes of Death in Polycythemia Vera

By

Lauren Dembeck, PhD

Publish Date December 14, 2020

Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.

Direct Oral Anticoagulants as Effective as Vitamin K Antagonists for Thromboembolic Events With Myeloproliferative Neoplasms

By

Vicki Moore, PhD

Publish Date December 10, 2020

The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.

Do Dietary Factors Influence Risk of Developing MPNs?

By

Susan Moench, PhD, PA-C

Publish Date December 2, 2020

An analysis of data from the NIH-AARP Diet and Health Study evaluated the association between consumption of various foods and the development of MPN.

Conditioning With Alkylating Agents Prior to Transplant for Myelofibrosis

By

Vicki Moore, PhD

Publish Date November 26, 2020

Patients with myelofibrosis conditioned with 2 alkylating agents may have better transplant outcomes compared with patients receiving 1 alkylating agent.